Recurrent urinary tract infections (UTI) are a major source of morbidity and healthcare costs. Risk factors associated with recurrence rates in premenopausal women can be attributed to patient lifestyle behavior. The aim of this study was to assess hygienic risk factors, determine pathogen distribution, and susceptibility patterns in premenopausal women with recurrent UTI. This was case-control study in which a face-to-face interview was conducted to obtain information from premenopausal women with recurrent UTI. Microbiology cultures and susceptibility results were obtained to analyze pathogen distribution and resistance. In this study, 214 cases and 230 controls were compared and the following practices were associated with increased risk of recurrent UTI in multivariable analysis: washing genitals from back to front (OR 1.64 [95% CI 1.05–2.56]), not voiding within 15 min after intercourse (OR 2.81 [95% CI 1.72–4.66]), not drinking water after intercourse (OR 1.69 [95% CI 1.12–2.58]), using any soap to clean after urination (OR 2.11 [95% CI 1.42–3.17]). Escherichia coli were the most prevalent pathogens isolated (66.4%), followed by Klebsiella spp. (12.6%), Pseudomonas aeruginosa (12.1%), and Proteus spp., (6.6%). This study identified several modifiable sexual and hygienic practices associated with recurrent UTI in premenopausal women. Continuous surveillance of antimicrobial susceptibility patterns is important to overcome resistance.

Keywords:
Premenopausal women, Urinary tract infection, Hygiene, Sexual habit, Susceptibility profile
1.
Kodner CM, Thomas Gupton EK: Recurrent urinary tract infections in women: diagnosis and management. Am Fam Physician 2010; 82: 638–643.
2.
Grabe M, Bjerklund-Johansen TE, Botto H, et al: European Association of Urology: Guidelines on Urological Infections, 2010.
3.
Hooton TM: Uncomplicated urinary tract infection. New Engl J Med 2012; 366: 1028–1037.
4.
Foxman B, Brown P: Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003; 17: 227–241.
5.
Ciani O, Grassi D, Tarricone R: An economic perspective on urinary tract infection: the “costs of resignation”. Clin Drug Investig 2013; 33: 255–261.
6.
Renard J, Ballarini S, Mascarenhas T, Zahran M, Quimper E, Choucair J, et al: Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther 2014; 4: 125–135.
7.
Dason S, Dason JT, Kapoor A: Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011; 5: 316–322.
8.
Nickel JC: Urinary tract infections and resistant bacteria. Rev Urol 2007; 9: 78–80.
9.
Abbo LM, Hooton TM: Antimicrobial stewardship and urinary tract infections. Antibiotics 2014; 31: 74–192.
10.
Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gopta K, Stamm WE: Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182: 1177–1182.
11.
Mishra B, Srivastava R, Agarwal J, Srivastava S, Pandey A: Behavioral and psychosocial risk factors associated with first and recurrent cystitis in Indian women: a case-control study. Indian J Commu Med 2016; 41: 27–33.
12.
Al-Badr A, Al-Shaikh G: Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos Univ Med J 2013; 13: 359–367.
13.
Amiri FN, Rooshan MH, Ahmady MH, Soliamani MJ: Hygiene practices and sexual activity associated with urinary tract infection in pregnant women. East Mediterr Health J 2009; 15: 104–110.
14.
Yazici S, Demirsoy G: Urinary tract infection and genital hygiene in pregnancy. Turk Clin Obstet Gynecol 2009; 19: 241–248.
15.
Arya LA, Northington GM, Asfaw T, Harvie H, Malykhina A: Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int 2012; 110: 247–251.
16.
Vincent CR, Thomas TL, Reyes L, White CL, Canales BK, Brown MB: Symptoms and risk factors associated with first urinary tract infection in college age women: a prospective cohort study. J Urol 2013; 189: 904–910
17.
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al: The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407–413.
18.
Minardi D, d’Anzeo G, Cantoro D, Conti A, Muzzonigro G: Urinary tract infections in women: etiology and treatment options. Int J Gen Med 2011; 4: 333–343.
19.
Tarek AS, Mohamed H: Uropathogens causing urinary tract infections in females and their susceptibility to antibiotics. Uro Today Int J 2011; 4: 1944–5784.
20.
Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540–2545.
21.
Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE: Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care 2008; 31: 1380–1385.
22.
Moreira JR, Siqueira IC, Alcantara AP, Guereiro De Moura CG, De Carvalho WA, Riley L: Antimicrobial resistance of Escherichia coli strains causing community-acquired urinary tract infections among insured and uninsured populations in a large urban center. J Chemother 2006; 18: 255–260.
23.
Alos JI, Serrano MG, Gomez-Garces JL, Perianes J: Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 2005; 11: 199–203.
24.
den Heijer CD, Beerepoot MA, Prins JM, Geerlings SE, Stobberingh EE: Determinants of antimicrobial resistance in Escherichia coli strains isolated from faeces and urine of women with recurrent urinary tract infections. PLoS One 2012; 7: e49909.
25.
Infectious Disease Society of America: Guidelines for antimicrobial treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis 2011; 52: e103–e120.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.